Related Experiment Video
Updated: Mar 16, 2026

Working with Human Tissues for Translational Cancer Research
Published on: November 26, 2015
A review of consent practices and perspectives for pharmacogenetic testing
Susanne B Haga1, Rachel Mills1
1Center for Applied Genomics & Precision Medicine, Duke University, School of Medicine, 304 Research Drive, Box 90141, Durham, NC 27708, USA.
Aim:
We aimed to understand consent practices for pharmacogenetic (PGx) testing.
Methods:
We conducted a literature review and analysis of consent forms from clinical laboratories offering PGx testing.
Results:
Our review of the literature shows a lack of consensus about the need for and type of informed consent for PGx testing. We identified 35 companies offering PGx testing and were able to confirm consent practices for 22 of those. We found a range of variability in the consent practices regarding the consent approach and information disclosed.
Conclusion:
Variability in the consent practices among laboratories offering PGx testing mirrors the ambiguous practices and recommendations reported in the literature. Establishing a minimal set of information to be disclosed to patients may help address the disparities in consent practice.
More Related Videos
Related Concept Videos
Pharmacogenetics and Pharmacogenomics: Overview
Principles of Pharmacogenetics: Types of Genetic Variants
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Pharmacogenetics of Drug Metabolism: Overview
Pharmacogenomics: Identification of New Drug Targets
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

